SCHEMBL4290842

SCHEMBL4290842

Cc1cccc(C2CN(C(=O)c3cccc(N4CCN(C)CC4)n3)C2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 1/20 0.46
HTR3E A5X5Y0 3/20 0.44
HTR3B O95264 3/20 0.44
HTR3A P46098 3/20 0.44
HTR3D Q70Z44 3/20 0.44
HTR3C Q8WXA8 3/20 0.44
PRKCQ Q04759 1/20 0.44
CHRM4 P08173 1/20 0.43
PROKR1 Q8TCW9 1/20 0.42
HPGD P15428 1/20 0.42
GBA1 P04062 1/20 0.41
CSF1R P07333 1/20 0.40
SCD5 Q86SK9 2/20 0.40
SCD O00767 1/20 0.40
DRD2 P14416 1/20 0.40
DRD1 P21728 1/20 0.40
DRD4 P21917 1/20 0.40
DRD5 P21918 1/20 0.40
DRD3 P35462 1/20 0.40
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295123 0.88 HSD17B14 (0.50) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4300878 0.81 PROKR1 (0.46) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4292208 0.81 SCD5 (0.48) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4292214 0.81 SCD5 (0.48) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4301528 0.81 SCD5 (0.53) HSD17B14PROKR1SCD5SCD
SCHEMBL7893494 0.79 SCD5 (0.46) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4301974 0.78 HSD17B14 (0.51) HSD17B14HTR3EHTR3BHTR3AHTR3D
SCHEMBL4306219 0.78 HCRTR1 (0.45) HSD17B14PRKCQ
SCHEMBL4306226 0.78 HCRTR1 (0.45) HSD17B14PRKCQ
SCHEMBL4299601 0.77 PRKCQ (0.44) HSD17B14PRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 HSD17B14 3609/4885HTR3E 37/4885HTR3B 20/4885
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885HTR3E 26/4885HTR3B 12/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 HSD17B14 3609/4885HTR3E 37/4885HTR3B 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.